ArticleJournal of cancer research and clinical oncology2026
GALNT1 emerges as a potential therapeutic target in breast cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeGALNT1, a key enzyme mediating O-GalNAc glycosylation, has not been fully characterized in the tumor microenvironment. This study aimed to investigate its expression pattern, molecular mechanisms, and clinical relevance in breast cancer.
methodsPublic datasets (TCGA, GEO, CPTAC) and single-cell transcriptomic data were integrated to analyze GALNT1 expression across cancer types and at the single-cell resolution. The expression and subcellular localization of GALNT1 in breast cancer were verified using qRT-PCR, Western blot, and immunofluorescence staining. Functional assays were conducted to assess its effects on cell proliferation, migration, and O-glycosylation, while CCK-8 assays were used to evaluate sensitivity to bortezomib.
resultsGALNT1 was significantly upregulated in primary breast cancer as well as multiple other malignancies. In vitro experiments demonstrated that GALNT1 promoted breast cancer cell proliferation, migration, and O-glycosylation. Immunofluorescence staining revealed widespread GALNT1 expression in tumor epithelial cells and cancer-associated fibroblasts (CAFs), with colocalization to the Tn antigen. Notably, GALNT1-mediated O-glycosylation was associated with resistance to bortezomib. High GALNT1 expression correlated with increased infiltration of CAFs and M2 macrophages, and reduced CD8⁺ T cell infiltration. Single-cell transcriptomic analysis further confirmed CAF-specific enrichment and elevated epithelial-mesenchymal transition (EMT) scores.
conclusionsGALNT1 is highly expressed in breast cancer, where it promotes tumor progression, bortezomib resistance through O-glycosylation, and immune microenvironment remodeling. The data imply that GALNT1 could represent a novel therapeutic candidate in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.